With the rapid development and complex challenges of chemical substances, new drug synthesis pathways are usually the most effective.170161-27-0,Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate,as a common compound, the synthetic route is as follows.
A mixture of 4-ethynylbenzaldehyde (65 mg, 500 mol) and triBoc-cyclam (250 mg, 500mol) in dichloromethane (4 mL) was stirred at ambient temperature for 2 h, and then sodiumtriacetoxyborohydride (318 mg, 1.5 mmol) was added. The mixture was stirred at ambient temperatureovernight. The reaction was quenched with aqueous NaHCO3, the layers were separated and theaqueous layer was extracted with dichloromethane. The combined organic layers were dried overanhydrous sodium sulfate and evaporated, and the crude residue was purified by Combi-Flash (silica gel;ethyl acetate in hexanes) to give p-RPS-546 (185 mg 60%) as a white solid.
170161-27-0, 170161-27-0 Tri-tert-butyl 1,4,8,11-tetraazacyclotetradecane-1,4,8-tricarboxylate 10940041, acatalyst-ligand compound, is more and more widely used in various.
Reference£º
Article; Amor-Coarasa, Alejandro; Kelly, James M.; Singh, Pradeep K.; Ponnala, Shashikanth; Nikolopoulou, Anastasia; Williams, Clarence; Vedvyas, Yogindra; Jin, Moonsoo M.; David Warren; Babich, John W.; Molecules; vol. 24; 8; (2019);,
Metal catalyst and ligand design
Ligand Template Strategies for Catalyst Encapsulation – NCBI